Sanofi’s pharma focus, strong Dupixent growth, and valuation discount position it for upside amid buybacks and rising ...

Guggenheim lowered the firm’s price target on Sanofi (SNY) to EUR 101 from EUR 104 and keeps a Buy rating on the shares after updating the firm’s ...

Sanofi SNY and partner Regeneron REGN announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending the approval of ...

Sanofi and Regeneron’s Dupixent to treat chronic spontaneous urticaria advances in EU with positive CHMP opinionRecommendation for adults and ...

Regeneron Pharmaceuticals is seeing revenue growth in key products that is now offsetting declining revenue in its previous ...

First-in-world approval of Dupixent for adults with uncontrolled COPD with raised blood eosinophils based on two landmark Phase 3 trials showing Dupixent significantly reduced exacerbations, improved ...

Nektar's stock price continued rising last month and into October because it also announced surprising 24-week results. After ...

Dupixent is back in the driver’s seat, reclaiming the top spot for ad impressions among Rx and over-the-counter (OTC) brands in May. The eczema and asthma drug from Sanofi and Regeneron had an ...

Approval based on pivotal results showing improvements in sustained disease remission and reductions in itch and oral corticosteroid use compared to placebo in adults with BP BP is a chronic, ...

Regeneron Pharmaceuticals, Inc. REGN and partner Sanofi SNY announced positive study data on the blockbuster asthma drug Dupixent from an interim analysis of the late-stage NOTUS study and other ...

TRENTON, N.J. --U.S. regulators have approved the first powerful, injected medicine to treat serious cases of the skin condition eczema. The Food and Drug Administration on Tuesday approved Dupixent ...

Dupixent meets early efficacy threshold for continuation in ongoing Phase 3 trial of patients with COPD; second confirmatory trial will commence in third quarter of 2020 Regeneron Pharmaceuticals, Inc ...